ArticleScientific reports2025
Construction of a risk and prognostic model for migrasome-associated lncRNAs in renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrative analysis identifies a glycosylation-related lncRNA signature associated with prognosis in kidney renal clear cell carcinoma.Translational andrology and urology · 2026Article
- Transmitophagy in the heart: An overview of molecular mechanisms and implications for pathophysiology.Acta pharmaceutica Sinica. B · 2026Review
- Integrating bulk RNA-seq and ScRNA-seq to identify manganese metabolism-related subtypes and immunoregulatory mechanisms in liver hepatocellular carcinoma.Open life sciences · 2026Article
- Exploring the role of long non-coding RNAs in renal cell carcinoma: insights into signaling pathways.Cancer cell international · 2025Review
- Migrasomes: a promising extracellular vesicle-like novel organelle for bone regeneration.Regenerative medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The migrasome, a recently identified cellular organelle, is closely associated with cell migration and plays a critical role in various physiological and pathological processes. The relationship between migrasomes and the prognosis of kidney cancer patients remains unclear. We utilized least absolute shrinkage and selection operator (LASSO) Cox regression analysis on data from The Cancer Genome Atlas- kidney renal clear cell carcinoma (TCGA-KIRC) dataset to identify migrasome-related long non-coding RNAs (lncRNAs) with prognostic significance in KIRC. We then developed and validated a prognostic risk model based on these lncRNAs. In addition, to identify potential immunotherapeutic agents, we analyzed tumor immune dysfunction and exclusion scores; we also conducted immune cell infiltration profiling. Risk score analysis identified 12 migrasome-related lncRNAs significantly associated with the prognosis of TCGA-KIRC patients. Kaplan-Meier survival analysis demonstrated that the prognostic model effectively stratified patients into high- and low-risk groups; the high-risk group showed a significantly worse prognosis relative to the low-risk group. Importantly, higher risk scores were associated with increased immune cell infiltration. This prognostic model underscores the importance of migrasome-related lncRNAs in KIRC and provides a novel tool for predicting patient prognosis and immune response in KIRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.